Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318621 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2AEGFRABCG2 | |
| SCHEMBL6321081 | 0.94 | EGFR (0.49) | SMN1; SMN2MEN1KMT2AEGFRCASP3 | |
| SCHEMBL6321088 | 0.94 | EGFR (0.49) | SMN1; SMN2MEN1KMT2AEGFRCASP3 | |
| SCHEMBL29642973 | 0.90 | EGFR (0.55) | MEN1KMT2AEGFRCASP3CAPN9 | |
| SCHEMBL28414296 | 0.90 | EGFR (0.55) | MEN1KMT2AEGFRCASP3CAPN9 | |
| SCHEMBL6322269 | 0.88 | PDPK1 (0.43) | SMN1; SMN2MEN1KMT2AEGFRHTT | |
| SCHEMBL6319709 | 0.88 | PDPK1 (0.43) | SMN1; SMN2MEN1KMT2AEGFRHTT | |
| SCHEMBL6319460 | 0.87 | EGFR (0.54) | MEN1KMT2AEGFRCASP3CAPN9 | |
| SCHEMBL6319442 | 0.87 | EGFR (0.54) | MEN1KMT2AEGFRCASP3CAPN9 | |
| SCHEMBL8010843 | 0.86 | ABCG2 (0.43) | SMN1; SMN2MEN1KMT2AEGFRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050136205-A1 | Thermoplastic multilayer composite | EMS-CHEMIE AG (CH) | 2005-06-23 | — | — | US | claimed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | SMN1; SMN2 4425/4885MEN1 3345/4885KMT2A 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.